{"id":"177lu-rad204","safety":{"commonSideEffects":[{"rate":"30%","effect":"Nausea"},{"rate":"20%","effect":"Vomiting"},{"rate":"40%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"177Lu-RAD204 is a radioligand therapy that selectively targets and destroys cancer cells expressing somatostatin receptors.","oneSentence":"Alpha-particle emitting radioligand targeting somatostatin receptors","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T06:31:53.297Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neuroendocrine tumors"}]},"trialDetails":[{"nctId":"NCT06305962","phase":"EARLY_PHASE1","title":"177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Radiopharm Theranostics, Ltd","startDate":"2024-06-03","conditions":"PDL1 Gene Mutation, Non Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC )","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"177Lu-RAD204","genericName":"177Lu-RAD204","companyName":"Radiopharm Theranostics, Ltd","companyId":"radiopharm-theranostics-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Alpha-particle emitting radioligand targeting somatostatin receptors Used for Neuroendocrine tumors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}